Ken Griffin Zai Lab LTD Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$16.25 - $24.14 $151,125 - $224,502	9,300 Added 116.25%	17,300 $417,000
Q2 2024 Aug 14, 2024	SELL	$13.72 - $21.55 $139,944 - $219,810	-10,200 Reduced 56.04%	8,000 $138,000
Q1 2024 May 15, 2024	BUY	$15.95 - $26.8 $118,030 - $198,320	7,400 Added 68.52%	18,200 $291,000
Q4 2023 Feb 14, 2024	BUY	$22.97 - $30.58 $27,564 - $36,696	1,200 Added 12.5%	10,800 $295,000
Q3 2023 Nov 14, 2023	BUY	$22.72 - $31.49 $38,624 - $53,533	1,700 Added 21.52%	9,600 $233,000
Q2 2023 Aug 14, 2023	SELL	$25.3 - $39.67 $298,540 - $468,106	-11,800 Reduced 59.9%	7,900 $219,000
Q1 2023 May 15, 2023	SELL	$30.21 - $48.1 $3.44 Million - $5.48 Million	-113,900 Reduced 85.25%	19,700 $655,000
Q4 2022 Feb 14, 2023	BUY	$22.28 - $38.71 $672,856 - $1.17 Million	30,200 Added 29.21%	133,600 $4.1 Million
Q3 2022 Nov 14, 2022	BUY	$34.2 - $51.69 $2.68 Million - $4.05 Million	78,400 Added 313.6%	103,400 $3.54 Million

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.59B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.